Journal of Hematology & Oncology

Article	Citations
Ferroptosis, necroptosis, and pyroptosis in anticancer immunity	674
Targeting the Wnt/β-catenin signaling pathway in cancer	621
SARS-CoV-2 binds platelet ACE2 to enhance thrombosis in COVID-19	478
Nanomaterials for cancer therapy: current progress and perspectives	466
EZH2: a novel target for cancer treatment	438
Tumor-derived exosomal miR-934 induces macrophage M2 polarization to promote liver metastasis of colorectal cancer	357
NK cell-based cancer immunotherapy: from basic biology to clinical development	305
Next generation of immune checkpoint inhibitors and beyond	294
Regulation of PD-L1 expression in the tumor microenvironment	277
Roles of METTL3 in cancer: mechanisms and therapeutic targeting	264
cGAS-STING, an important pathway in cancer immunotherapy	250
Challenges and advances in clinical applications of mesenchymal stromal cells	247
Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001–2020)	226
RNA sequencing: new technologies and applications in cancer research	226
Cancer vaccines as promising immuno-therapeutics: platforms and current progress	225
The MAPK and AMPK signalings: interplay and implication in targeted cancer therapy	223
Isolation and characterization of exosomes for cancer research	209
Combination strategies to maximize the benefits of cancer immunotherapy	206
Dendritic cell biology and its role in tumor immunotherapy	203
Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy	196
Immunosenescence: a key player in cancer development	195
Targeting mutant p53 for cancer therapy: direct and indirect strategies	193
Targeting hypoxic tumor microenvironment in pancreatic cancer	192
Novel therapies emerging in oncology to target the TGF-β pathway	191
Recent advances in CAR-T cell engineering	190

Neutrophils in cancer carcinogenesis and metastasis	189
Emerging role of exosomes in cancer progression and tumor microenvironment remodeling	182
Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia	178
Applications of single-cell sequencing in cancer research: progress and perspectives	177
Identification of a small molecule as inducer of ferroptosis and apoptosis through ubiquitination of GPX4 in triple negative breast cancer cells	177
COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA)	174
Spatial architecture of the immune microenvironment orchestrates tumor immunity and therapeutic response	174
Pluripotent stem cell-derived CAR-macrophage cells with antigen-dependent anti-cancer cell functions	170
The molecular mechanisms and therapeutic strategies of EMT in tumor progression and metastasis	167
m6A-binding proteins: the emerging crucial performers in epigenetics	166
Liquid biopsy: current technology and clinical applications	164
Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma	161
Oncolytic viruses for cancer immunotherapy	158
Recent advances in therapeutic strategies for triple-negative breast cancer	157
Emerging therapeutic agents for advanced non-small cell lung cancer	156
Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors in clinical trials for cancer immunotherapy	155
Impact of hematologic malignancy and type of cancer therapy on COVID-19 severity and mortality: lessons from a large population-based registry study	154
RNA-binding proteins in tumor progression	150
Targeting CD47 for cancer immunotherapy	147
Targeting cell death pathways for cancer therapy: recent developments in necroptosis, pyroptosis, ferroptosis, and cuproptosis research	145
Targeting MCL-1 in cancer: current status and perspectives	142
Fifth-week immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on active treatment: preliminary data from a single insti	142
Burden of anemia and its underlying causes in 204 countries and territories, 1990–2019: results from the Global Burden of Disease Study 2019	142
HMGB1 released from GSDME-mediated pyroptotic epithelial cells participates in the tumorigenesis of colitis-associated colorectal cancer through the ERK1/2 pathway	140
Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation	139
Next-generation immuno-oncology agents: current momentum shifts in cancer immunotherapy	136
Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy	133
MEK inhibitors for the treatment of non-small cell lung cancer	132
Therapeutic roles of mesenchymal stem cell-derived extracellular vesicles in cancer	132
Immunosuppressive cells in cancer: mechanisms and potential therapeutic targets	127
A WEE1 family business: regulation of mitosis, cancer progression, and therapeutic target	126
Antibody–drug conjugates in solid tumors: a look into novel targets	125
Targeted therapy in advanced non-small cell lung cancer: current advances and future trends	125
Cancer stem cell secretome in the tumor microenvironment: a key point for an effective personalized cancer treatment	125
Cancer history is an independent risk factor for mortality in hospitalized COVID-19 patients: a propensity score-matched analysis	124
Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies	123
Targeting extracellular matrix stiffness and mechanotransducers to improve cancer therapy	122
Global, regional, and national cancer incidence and death for 29 cancer groups in 2019 and trends analysis of the global cancer burden, 1990–2019	122
The consensus from The Chinese Society of Hematology on indications, conditioning regimens and donor selection for allogeneic hematopoietic stem cell transplantation: 2021 update	121
VISTA: an immune regulatory protein checking tumor and immune cells in cancer immunotherapy	119
HMGB1 in inflammation and cancer	117
Modeling neoplastic disease with spheroids and organoids	117
Hypoxia-inducible factors: master regulators of hypoxic tumor immune escape	116
The construction, expression, and enhanced anti-tumor activity of YM101: a bispecific antibody simultaneously targeting TGF-β and PD-L1	114
XPO1-dependent nuclear export as a target for cancer therapy	114
Chimeric antigen receptor-engineered natural killer cells for cancer immunotherapy	114
The global burden and attributable risk factor analysis of acute myeloid leukemia in 195 countries and territories from 1990 to 2017: estimates based on the global burden of disease study 2017	110
Emerging agents that target signaling pathways in cancer stem cells	109
Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies	109
Targeting autophagy to overcome drug resistance: further developments	106

Insulin-like growth factor receptor signaling in tumorigenesis and drug resistance: a challenge for cancer therapy	106
tRNA-derived RNA fragments in cancer: current status and future perspectives	105
BCMA-targeted immunotherapy for multiple myeloma	105
Exploring immunotherapy in colorectal cancer	105
IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelin	104
How to select IgG subclasses in developing anti-tumor therapeutic antibodies	103
The management of metastatic GIST: current standard and investigational therapeutics	102
N6-methyladenosine methyltransferases: functions, regulation, and clinical potential	100
The impact of the temporary suspension of national cancer screening programmes due to the COVID-19 epidemic on the diagnosis of breast and colorectal cancer in the Netherlands	100
Role of lysosomes in physiological activities, diseases, and therapy	99
Emerging agents and regimens for AML	99
High mobility group box 1 (HMGB1): a pivotal regulator of hematopoietic malignancies	98
Mesenchymal stem/stromal cells in cancer therapy	98
Evolving therapy of adult acute lymphoblastic leukemia: state-of-the-art treatment and future directions	97
Advances in synthetic lethality for cancer therapy: cellular mechanism and clinical translation	96
Expression patterns of immune checkpoints in acute myeloid leukemia	95
Enhancing the therapeutic efficacy of nanoparticles for cancer treatment using versatile targeted strategies	94
A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward	94
The potential role of N7-methylguanosine (m7G) in cancer	93
Targeting Akt in cancer for precision therapy	92
Gene modification strategies for next-generation CAR T cells against solid cancers	92
Emerging strategies to target RAS signaling in human cancer therapy	91
Postoperative circulating tumor DNA as markers of recurrence risk in stages II to III colorectal cancer	90
Genetic alteration, RNA expression, and DNA methylation profiling of coronavirus disease 2019 (COVID-19) receptor ACE2 in malignancies: a pan-cancer analysis	89
MCL-1 inhibitors, fast-lane development of a new class of anti-cancer agents	88
Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts	88
The application and prospect of CDK4/6 inhibitors in malignant solid tumors	88
Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma	87
The long and short non-coding RNAs modulating EZH2 signaling in cancer	87
Targeting EphA2 in cancer	87
A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma	86
YTHDF2 facilitates UBXN1 mRNA decay by recognizing METTL3-mediated m6A modification to activate NF-κB and promote the malignant progression of glioma	84
LCAT3, a novel m6A-regulated long non-coding RNA, plays an oncogenic role in lung cancer via binding with FUBP1 to activate c-MYC	82
The relationship between expression of PD-L1 and HIF-1α in glioma cells under hypoxia	81
Contradictory roles of lipid metabolism in immune response within the tumor microenvironment	81
Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter study	81
Reactive cutaneous capillary endothelial proliferation in advanced hepatocellular carcinoma patients treated with camrelizumab: data derived from a multicenter phase 2 trial	80
COVID-19 vaccines for patients with cancer: benefits likely outweigh risks	79
HLF regulates ferroptosis, development and chemoresistance of triple-negative breast cancer by activating tumor cell-macrophage crosstalk	78
A novel lncRNA ROPM-mediated lipid metabolism governs breast cancer stem cell properties	77
Novel therapies are changing treatment paradigms in metastatic prostate cancer	76
A randomized, open-label, Phase III study of obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-Cell lymphoma: final analysis of GOYA	76
Role of CD47 in Hematological Malignancies	75
New agents and regimens for diffuse large B cell lymphoma	73
MYC: a multipurpose oncogene with prognostic and therapeutic implications in blood malignancies	73
Epidemiological trends of tracheal, bronchus, and lung cancer at the global, regional, and national levels: a population-based study	72
HNRNPA2B1 promotes multiple myeloma progression by increasing AKT3 expression via m6A-dependent stabilization of ILF3 mRNA	72
Severe COVID-19 virus reactivation following treatment for B cell acute lymphoblastic leukemia	70
Circular RNAs: characteristics, biogenesis, mechanisms and functions in liver cancer	70
Post-transplant cyclophosphamide after matched sibling, unrelated and haploidentical donor transplants in patients with acute myeloid leukemia: a comparative study of the ALWP EBMT	69
Amplification of spatially isolated adenosine pathway by tumor–macrophage interaction induces anti-PD1 resistance in hepatocellular carcinoma	67
SBRT combined with PD-1/PD-L1 inhibitors in NSCLC treatment: a focus on the mechanisms, advances, and future challenges	67
Combine and conquer: manganese synergizing anti-TGF-β/PD-L1 bispecific antibody YM101 to overcome immunotherapy resistance in non-inflamed cancers	67
Crosstalks between inflammasome and autophagy in cancer	66
Oct4 promotes M2 macrophage polarization through upregulation of macrophage colony-stimulating factor in lung cancer	66
Prostate cancer and PARP inhibitors: progress and challenges	66
Targeting immune checkpoints in hematological malignancies	65
CD38-directed CAR-T cell therapy: a novel immunotherapy strategy for relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation	65
CD155 immunoregulation as a target for natural killer cell immunotherapy in glioblastoma	65
Gastric cancer treatment: recent progress and future perspectives	65
Emerging role of RNA methyltransferase METTL3 in gastrointestinal cancer	65
DT2216—a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas	64
FGFR-TKI resistance in cancer: current status and perspectives	64
Development of a novel combined nomogram model integrating deep learning-pathomics, radiomics and immunoscore to predict postoperative outcome of colorectal cancer lung metastasis patients	63
Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021	63
Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies	63
T-cell receptor-based therapy: an innovative therapeutic approach for solid tumors	63
Born to survive: how cancer cells resist CAR T cell therapy	61
SARS-CoV-2 interacts with platelets and megakaryocytes via ACE2-independent mechanism	61
STOML2 potentiates metastasis of hepatocellular carcinoma by promoting PINK1-mediated mitophagy and regulates sensitivity to lenvatinib	60
Targeting p53–MDM2 interaction by small-molecule inhibitors: learning from MDM2 inhibitors in clinical trials	60
Principles and innovative technologies for decrypting noncoding RNAs: from discovery and functional prediction to clinical application	60
Warburg effect in colorectal cancer: the emerging roles in tumor microenvironment and therapeutic implications	60
RNA demethylase ALKBH5 in cancer: from mechanisms to therapeutic potential	60
Third-line therapy for chronic myeloid leukemia: current status and future directions	60
Mechanisms and rejuvenation strategies for aged hematopoietic stem cells	59
Reshaping the systemic tumor immune environment (STIE) and tumor immune microenvironment (TIME) to enhance immunotherapy efficacy in solid tumors	58
Impact of the COVID-19 pandemic on diagnosis, stage, and initial treatment of breast cancer in the Netherlands: a population-based study	57
Natural killer cell-based immunotherapy for acute myeloid leukemia	56
Thrombocytopenia and thrombosis in hospitalized patients with COVID-19	56

Advances in the diagnosis and treatment of sickle cell disease	56
N6-methyladenosine reader IMP2 stabilizes the ZFAS1/OLA1 axis and activates the Warburg effect: implication in colorectal cancer	55
The emerging role of KDM5A in human cancer	55
Pre-transplant MRD negativity predicts favorable outcomes of CAR-T therapy followed by haploidentical HSCT for relapsed/refractory acute lymphoblastic leukemia: a multi-center retrospective study	54
Targeting Bruton tyrosine kinase using non-covalent inhibitors in B cell malignancies	53
LncRNA-PACERR induces pro-tumour macrophages via interacting with miR-671-3p and m6A-reader IGF2BP2 in pancreatic ductal adenocarcinoma	53
Burden, trends, and risk factors of esophageal cancer in China from 1990 to 2017: an up-to-date overview and comparison with those in Japan and South Korea	53
Mitochondrial adaptation in cancer drug resistance: prevalence, mechanisms, and management	53
Combination of oral STING agonist MSA-2 and anti-TGF-β/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumors	53
Emerging agents and regimens for multiple myeloma	52
Tumor organoids: applications in cancer modeling and potentials in precision medicine	51
Metabolic profiles of regulatory T cells and their adaptations to the tumor microenvironment: implications for antitumor immunity	51
Therapeutic strategies in RET gene rearranged non-small cell lung cancer	50
Abnormally activated OPN/integrin αVβ3/FAK signalling is responsible for EGFR-TKI resistance in EGFR mutant non-small-cell lung cancer	50
CDK7 inhibitor THZ1 enhances antiPD-1 therapy efficacy via the p38α/MYC/PD-L1 signaling in non-small cell lung cancer	50
Toll-like receptors and toll-like receptor-targeted immunotherapy against glioma	50
Targeting B7-H3 via chimeric antigen receptor T cells and bispecific killer cell engagers augments antitumor response of cytotoxic lymphocytes	50